You are here

Article Text

Article menu
Download PDFPDF
Correspondence
Development of erythroleukaemia after myelodysplastic syndrome in a patient with Wegener's granulomatosis
  1. T TAKAOKA,
  2. Y MATSUKAWA,
  3. Y TOMITA,
  4. N KITAMURA,
  5. T YAMAZAKI,
  6. J TAKEUCHI,
  7. S NISHINARITA,
  8. U SAWADA,
  9. T HORIE
  1. First Department of Internal Medicine
  2. Nihon University School of Medicine
  3. Oyaguchi-Kamimachi Itabashi
  4. 173–8610, Tokyo Japan
  1. m-2000{at}mbk.sphere.ne.jp

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Clinical use of cyclophosphamide (CYC) improves the prognosis of Wegener's granulomatosis (WG),1 ,2 though treatment related malignancies have been recorded.3-5 Among treatment related malignancies, the development of erythroleukaemia has been rarely reported.6 In addition, there have been no reports of erythroleukaemia arising in patients with WG.

    A 59 year old woman presented with nasal bleeding, nasal obstruction, and fever in December 1994. A biopsy specimen from nasal mucosa was compatible with WG, and cytoplasmic antineutrophil cytoplasmic antibodies (cANCA) were 13 EU (normally undetectable). A chestx ray examination on admission showed the presence of a cavity in the right lung field. She received 30 mg/day of prednisolone, with limited improvements. CYC (100 mg/day) was therefore given orally from 19 December. As …

    View Full Text